Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi:
10.1001/amajethics.2018.881.
This portrait of a child against a backdrop of health data suggests how a patient’s individuality can be obscured when precision medicine is used in decision making and developing target therapies.
AMA J Ethics. 2018;20(9):E891-893. doi:
10.1001/amajethics.2018.891.
Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.
Iris G. Insogna, MD, MBE and Elizabeth S. Ginsburg, MD
Although the World Health Organization defines infertility as a disease, insurance coverage gaps generate disparities in access to care and treatment, especially for tubal factor infertility and oncofertility.
AMA J Ethics. 2018;20(12):E1152-1159. doi:
10.1001/amajethics.2018.1152.
With a focus on health justice, literature review suggests possible relationships between HPV type and geography and demonstrates that insurance status matters.
AMA J Ethics. 2019;21(3):E269-272. doi:
10.1001/amajethics.2019.269.